Merus Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021 09:00 ET
|
Merus N.V.
Tumor shrinkage and partial responses observed in patients with advanced head and neck squamous cell carcinoma (HNSCC) treated with MCLA-158In preclinical studies, Zeno observed to block cell growth...
Merus Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021 16:35 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing...
Merus to Participate in Upcoming Investor Conferences
September 07, 2021 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus Announces Financial Results for the Second Quarter and Provides Business Update
August 05, 2021 17:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing...
Merus Announces Publication in Nature Communications on MCLA-145’s Novel Mechanism of Action Promoting Tumor Immunity and Context Dependent T-Cell Costimulation
July 21, 2021 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus to Participate in William Blair's Biotech Focus Conference 2021
July 07, 2021 16:20 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting (Oral Abstract)
June 04, 2021 12:00 ET
|
Merus N.V.
- 61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date- Encouraging early clinical activity observed, with...
Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
May 26, 2021 16:01 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...
Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
May 19, 2021 17:01 ET
|
Merus N.V.
- 51 patients with NRG1+ cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021, data cutoff date- Encouraging early clinical activity observed, with...
Merus Announces Collaborations in Israel, Italy and Spain to Increase Screening and Identification of Cancer Patients with NRG1 Fusion Tumors and to Raise Awareness of the Phase 1/2 eNRGy Clinical Trial
May 13, 2021 08:00 ET
|
Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific...